The need for a personalized approach for prostate cancer management

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Michiel Sedelaar, J P ^a   Schalken, Jack A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker; Genome; Individualized medicine; Prognosis; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER CLASSIFICATION; CANCER OF THE PROSTATE RISK ASSESSMENT POST SURGICAL SCORE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CLASSIFIER; CLINICAL ASSESSMENT TOOL; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; EARLY INTERVENTION; ECHOGRAPHY; GENE EXPRESSION PROFILING; GLEASON SCORE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MALE; NOTE; PERSONALIZED MEDICINE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

EID: 84928995322     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0344-1     Document Type: Note

References (8)

1. Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol. 2005;15:187-95.
2. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004;350:2239-46.
3. Birnbaum JK, Feng Z, Gulati R, Fan J, Lotan Y, Wei JT, et al. Projecting benefits and harms of novel cancer screening biomarkers: a study of PCA3 and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2015;24:677-82.
4. Loeb S, Bruinsma SM, Nicholsen J, Briganti A, Pickles T, Kakehi Y, et al. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol. 2015;67:619-26.
5. Naoi Y, Noguchi S. Multi-gene classifiers for prediction of recurrence in breast cancer patients. Breast Cancer. 2015 [Epub ahead of print].
6. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnager S, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013;31:1428-34.
7. Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol. 2014. Epub ahead of print.
8. Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol. 2015;33:944-51.